首页> 美国卫生研究院文献>Experimental Diabetes Research >Therapeutic Potential of Dioscorea Extract (DA-9801) in Comparison with Alpha Lipoic Acid on the Peripheral Nerves in Experimental Diabetes
【2h】

Therapeutic Potential of Dioscorea Extract (DA-9801) in Comparison with Alpha Lipoic Acid on the Peripheral Nerves in Experimental Diabetes

机译:薯Di提取物(DA-9801)与α-硫辛酸对实验性糖尿病患者周围神经的治疗潜力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

DA-9801, a mixture of extracts from Dioscorea japonica Thunb. and Dioscorea nipponica Makino, was reported to have neurotrophic activity. Therefore, we investigated the therapeutic potential of DA-9801, in comparison with alpha lipoic acid (ALA), for peripheral nerves preservation in experimental diabetes. Experimental animals were divided into 4 groups, and each group was designated according to the type of treatment administered as follows: normal, DM, DM+DA-9801, and DM+ALA. After 16 weeks, response thresholds to tactile and thermal stimuli were higher in DM+DA-9801 group than in nontreated DM group. This degree of increase in DM+DA-9801 group indicates more therapeutic potency of DA-9801 than ALA. Western blot analysis showed more significant increase in NGF and decrease in TNF-α and IL-6 in DM+DA-9801 group than in DM or DM+ALA groups (P < 0.05). IENF density was reduced less significantly in the DM+DA-9801 group than in other DM groups (7.61 ± 0.32, 4.2 ± 0.26, and 6.5 ± 0.30 in DM+DA-9801, DM, and DM+ALA, resp., P < 0.05). Mean myelinated axonal area in the sciatic nerves was significantly greater in DM+DA-9801 group than in other DM groups (69.2 ± 5.76, 54.0 ± 6.32, and 63.1 ± 5.41 in DM+DA-9801, DM, and DM+ALA, resp., P < 0.05). Results of this study demonstrated potential therapeutic applications of DA-9801 for the treatment of diabetic peripheral neuropathy.
机译:DA-9801,是薯Di的提取物混合物。据报道,Dioscorea nipponica Makino具有神经营养活性。因此,与α-硫辛酸(ALA)相比,我们研究了DA-9801对实验性糖尿病患者周围神经保存的治疗潜力。将实验动物分为4组,并根据以下给予的治疗类型来指定每组:正常,DM,DM + DA-9801和DM + ALA。 16周后,DM + DA-9801组的触觉和热刺激反应阈值高于未治疗的DM组。 DM + DA-9801组的这种增加程度表明,DA-9801的治疗效力要高于ALA。 Western blot分析显示,DM + DA-9801组的NGF含量增加明显高于DM组或DM + ALA组(P <0.05),而TNF-α和IL-6含量下降更为显着(P <0.05)。 DM + DA-9801组的IENF密度降低幅度不及其他DM组显着(DM + DA-9801,DM和DM + ALA分别为7.61±0.32、4.2±0.26和6.5±0.30,分别为P <0.05)。 DM + DA-9801组坐骨神经的平均髓鞘轴突面积显着大于其他DM组(DM + DA-9801,DM和DM + ALA分别为69.2±5.76、54.0±6.32和63.1±5.41,分别,P <0.05)。这项研究的结果证明了DA-9801在糖尿病周围神经病变治疗中的潜在治疗应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号